Marksans Pharma Ltd (MARKSANS)
₹335.90
Mkt cap
₹15,183 Cr
P/E ratio
29.40
P/B
5.04
Div yield
0.27%
ROE
15.20%
ROCE
18.80%
EPS (TTM)
₹11.43
Book value
₹67
52W range
157–337
Sector
Healthcare
Price history
Previous close
Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products [1]
NSE MARKSANSBSE 524404
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−0.33% from high₹336
₹157+114.10% from low₹337
Current
₹335.90
Prev close
₹337.00
Day
−0.33%
Price performance
1D
−0.33%
1W
+4.19%
1M
+23.74%
3M
+36.04%
6M
+93.25%
1Y
+96.49%
YTD
+84.37%
Financials
Revenue, profit & margin
P/E ratio
29.4×
MARKSANS is 16% below the sector median of 35.1×
MARKSANS29.4×
Sector median35.1×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 500 | 531 | 586 | 560 | 591 | 642 | 682 | 708 | 620 | 720 | 754 | 856 | 841 | |
| Expenses | 398 | 417 | 453 | 450 | 462 | 495 | 543 | 582 | 520 | 576 | 594 | 661 | 628 | |
| Operating Profit | 102 | 114 | 133 | 110 | 128 | 147 | 139 | 127 | 100 | 144 | 161 | 195 | 213 | |
| OPM % | 20% | 21% | 23% | 20% | 22% | 23% | 20% | 18% | 16% | 20% | 21% | 23% | 25% | |
| Other Income | 10 | 19 | 5 | 17 | 15 | -0 | 28 | 15 | 6 | 22 | 20 | 35 | 25 | |
| Interest | 2 | 2 | 3 | 5 | 3 | 3 | 3 | 3 | 6 | 6 | 6 | 6 | 7 | |
| Depreciation | 14 | 18 | 22 | 21 | 20 | 20 | 21 | 23 | 23 | 27 | 24 | 24 | 25 | |
| Profit before tax | 97 | 114 | 113 | 100 | 120 | 125 | 143 | 116 | 77 | 133 | 151 | 200 | 207 | |
| Tax % | 27% | 26% | 26% | 23% | 26% | 22% | 27% | 22% | 24% | 26% | 25% | 25% | 23% | |
| Net Profit | 70 | 84 | 83 | 78 | 89 | 98 | 105 | 91 | 58 | 99 | 114 | 149 | 159 | |
| EPS in Rs | 1.52 | 1.84 | 1.84 | 1.73 | 1.96 | 2.13 | 2.31 | 2.00 | 1.29 | 2.17 | 2.50 | 3.27 | 3.47 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +12.06% · closed higher next day 1 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 12 Aug '26 |
| Earnings day | +12.06% |
| +1 day | +8.77% |
| +5 days | +17.23% |
| +15 days | +19.20% |
| +30 days | — |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 202643.87%Promoter
Promoters43.87%
FIIs17.47%0.71
DIIs6.19%0.38
Public32.46%0.32
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,895.00 | 35.99 | 4,54,674 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,315.00 | 83.00 | 2,47,284 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,914.00 | 83.77 | 1,86,913 | 0.77% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| ZYDUSLIFE | ₹1,156.90 | 23.70 | 1,15,401 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| CIPLA | ₹1,395.00 | 31.49 | 1,12,696 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| LAURUSLABS | ₹1,876.70 | 92.74 | 1,01,400 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,105.00 | 16.17 | 96,254 | 0.86% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| MARKSANS | ₹335.05 | 29.38 | 15,183 | 0.27% | 159 | +169.50% | 841 | +35.62% | 18.80% |
| Median: 159 Co. | ₹423.00 | 35.07 | 2,282 | 0.08% | 13 | +29.60% | 162 | +18.62% | 15.04% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013nseAnnual Report 2013bse
Concall transcripts58
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptJun 2026PPTJun 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024RECNov 2024TranscriptAug 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 7 Sep - Copy of Newspaper Publication regarding transfer of unclaimed dividend and equity shares of the Company to the IEPFAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 1 Sep - Marksans Pharma will attend Ashwamedh-Elara India Dialogue 2026 investor meet on 2 September 2026 in Mumbai.Voting Results Of The 34Th Annual General Meeting Of The Company 27 Aug - Marksans Pharma AGM voting results announced; all resolutions passed, including 0.90 final dividend and Sandra Saldanha reappointment.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 27 Aug - Marksans Pharma’s 34th AGM resolutions passed; final dividend of Re.0.90 approved, along with director reappointments.Shareholder Meeting / Postal Ballot-Outcome of AGM 27 Aug